Soligenix is developing stabilization technology under an option-to-license agreement from CU, which was executed to provide support $9.4m National Institute of Allergy and Infectious Diseases (NIAID) grant for the development of the technology.
Soligenix and CU said the license agreement has an expanded scope for thermostable vaccines for biodefense as well as all potential vaccine indications.
The novel technology involves the use of several process and formulation steps that fix sensitive vaccine ingredients in native configuration.
Soligenix chief scientific officer Robert Brey said the achievement of extended stability as well as stability under elevated temperature would represent a significant step forward in vaccine technology.
"Further, this novel thermostability technology has the potential to allow us to expand our vaccine business into the development of countermeasures against other more common infectious diseases," Brey said.